|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM111905478 |
| 003 |
DE-627 |
| 005 |
20231222160613.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0373.xml
|
| 035 |
|
|
|a (DE-627)NLM111905478
|
| 035 |
|
|
|a (NLM)11280890
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Suzuki, H
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.04.2001
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We compared the efficacy of once a day administration of terazosin hydrochloride with that of twice a day administration for benign prostatic hyperplasia (BPH) patients. Forty-two patients with BPH were randomly assigned to receive a maximum dose of 2 mg terazosin either once (n = 21) or twice (n = 21) a day. International prostate symptom score (IPSS), uroflowmetry and side effect profile were determined before and 4 weeks after randomization. Both groups were similar with respect to patient age, baseline IPSS and prostate volume. After 4 weeks of treatment with terazosin, significant improvement in IPSS, maximum flow rate and mean flow rate were observed in both groups. However, these improvements did not differ significantly between them. In addition, there were no differences in side effects between the groups. In conclusion, once a day administration of terazosin hydrochloride is as effective and safe as twice a day administration in patients with BPH
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Adrenergic alpha-Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Terazosin
|2 NLM
|
| 650 |
|
7 |
|a 8L5014XET7
|2 NLM
|
| 650 |
|
7 |
|a Prazosin
|2 NLM
|
| 650 |
|
7 |
|a XM03YJ541D
|2 NLM
|
| 700 |
1 |
|
|a Ohnishi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ikemoto, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohishi, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suzuki, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamazaki, H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 47(2001), 2 vom: 01. Feb., Seite 77-81
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2001
|g number:2
|g day:01
|g month:02
|g pages:77-81
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2001
|e 2
|b 01
|c 02
|h 77-81
|